نتایج جستجو برای: PersonalizedMedicine

تعداد نتایج: 7  

2015
Alessandro Di Stefano Aurelio La Corte

In the future, life and death decisions will depend on having more data and more organized knowledge. These data will overcome traditional scale and dimensions, thus we will need to think about new kind of strategies which involve Information and Communication Technologies. Collect, organize and compute every aspect will be crucial for survival of patients and for healthcare management. Followi...

2016
Chunhui Zhang Jingchun Zhang Guangyu Wang Jiajia Xu Yanlin Li Qing Guo Tongsen Zheng Yanqiao Zhang

Primitive neuroectodermal tumor (PNET) is a highly aggressive small round celltumor but is extremely rare in the lung. Next-generation sequencing (NGS) has led to breakthroughs for genetic analyses and personalizedmedicine approaches for cancer treatment.We report the case of a 30-year-old woman with an advanced pulmonary PNET treated with multiple chemotherapeutic regimens, and achieved a part...

Journal: :Frontiers in genetics 2016
Frank Emmert-Streib Lauri Tuomisto Olli Yli-Harja

There is general agreement that the manner medicine is currently practiced is not adequate for addressing all health relevant issues in a way that would be most beneficial for all patients and that we need a new modern medicine. Even candidates for such a modern medicine have been recently nominated in the form of (I) personalizedmedicine, (II) precisionmedicine, (III) P4medicine, (IV) P5 medic...

2012
Barry R. Davies Hannah Greenwood Phillippa Dudley Claire Crafter De-Hua Yu Jingchuan Zhang Qunsheng Ji Ken Page James Yates Clare Lane Rebecca Watson Richard Luke Martin Pass

AKT is a key node in themost frequently deregulated signaling network in human cancer. AZD5363, a novel pyrrolopyrimidine-derived compound, inhibited all AKT isoforms with a potency of 10 nmol/L or less and inhibited phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 mmol/L. AZD5363 monotherapy inhibited the proliferation of 41 of 182 solid and hematologic tum...

2010
M. Markman Jalid Sehouli Charles F. Levenback Dennis S. Chi

Over the past five decades ovarian cancer has been of considerable interest to clinical cancer investigators due to the fact that it is among the most chemosensitive of all solid tumors [1]. Unfortunately, despite the advances in the chemotherapeutic management of this malignancy, the large majority of patients ultimately recur, progress, and ultimately die as a direct result of complications o...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2014
Susan E Bates

These words distill the essence of the topic we present in this CCR Focus section. The idea of "personalizedmedicine"asaparadigminoncologyhas captured the imaginationofphysiciansand patients alike. A Google search finds 940,000 hits on the term, and another 109,000 for the term "precisionmedicine." In this paradigm, a cancer is analyzedbyone ormore tests thatwill direct the patient and the phys...

2014
Naoki Mine Sayaka Yamamoto Donald W. Kufe Daniel D. Von Hoff Takumi Kawabe

CBP501 is an anticancer drug candidate that was investigated in two randomized phase II clinical trials for patientswith nonsquamous non–small cell lung cancer (NSCLC) andmalignant pleuralmesothelioma (MPM). CBP501 has been shown to have twomechanisms of action, namely calmodulinmodulation andG2 checkpoint abrogation. Here, we searched for a biomarker to predict sensitivity to CBP501. Twenty-ei...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید